Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 25, Issue 4-5, Pages 535-546Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2011.10.013
Keywords
Aminosalicylates; Inflammatory bowel disease; Ulcerative colitis; Colorectal cancer
Categories
Funding
- Federal Ministry of Economy, Family and Youth
- National Foundation for Research, Technology and Development
- Austrian Science Fund
- Christian Doppler Research Association
Ask authors/readers for more resources
Aminosalicylates are the most common drugs for the primary treatment of inflammatory bowel disease. Various pro-drugs and formulations were developed in order to improve pharmacological profiles, optimize bioavailability and to gain highest efficacy in the treatment of ulcerative colitis (UC) and Crohn's disease. In vitro studies have greatly contributed to the understanding of the molecular actions in vivo and clinical studies have proven aminosalicylates to be effective and safe. This review summarizes the current knowledge on the molecular, pharmacological and clinical properties of aminosalicylates with respect to chemoprevention for UC-associated colorectal cancer. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
